Kizzmekia Corbett’s team was the first to demonstrate a vaccine that successfully stopped viral replication in both the lungs and nose.

Kizzmekia Corbett’s team was the first to demonstrate a vaccine that successfully stopped viral replication in both the lungs and nose.
After three months of studies, the vaccine her team developed is about to enter a phase I clinical trial, a crucial hurdle on the way to FDA approval.
“Don’t let the temporary absence of community deter you from pursuing your goals’” says Opoku-Agyeman, who attributes her success to her support network.
Hundreds of Meyerhoff Scholars Program alumni gathered to celebrate the program’s 30th anniversary, and to thank Robert E. Meyerhoff for his bold vision.
In 1989, Baltimore philanthropist Robert E. Meyerhoff sat down with then-UMBC vice provost Freeman Hrabowski<span...
The Meyerhoff Scholars program has been called the “gold standard” for providing a path into STEM research for underrepresented students in the field.